Blocking T cell co-stimulation in primary Sjögren's syndrome: rationale, clinical efficacy and modulation of peripheral and salivary gland biomarkers

E. Pontarini, G. M. Verstappen, S. Grigoriadou, F. G. M. Kroese, H. Bootsma, M. Bombardieri

Research output: Contribution to journalReview articlepeer-review

12 Citations (Scopus)
30 Downloads (Pure)

Abstract

There is accumulating evidence that patients with primary Sjögren's syndrome (pSS) display aberrant CD4+ T cell responses, both in the peripheral compartment and in the inflamed salivary glands. CD4+ T cell abnormalities are also critically associated with B cell hyper activation, one of the hallmarks of disease, which is linked with disease severity and evolution to lymphoma. T cell activation and the cross-talk between T and B cells are tightly regulated by the balance between co-stimulatory pathways, such as the interactions between CD80/CD86:CD28, CD40:CD40L and ICOS:ICOSL, and co-inhibitory signals, including the immunoregulatory CTLA-4 protein. Evidence from patients with pSS as well as data from animal models of the disease suggests that these pathways play a critical role in pSS pathogenesis and their targeting could be exploited for therapeutic purposes. In this review, we first summarise the evidence implicating aberrant T cell co-stimulation and co-inhibition in driving the disease before focusing on the results of recent randomised controlled trials (RCTs) with compounds able to block T cell co-stimulation and enhance T cell co-inhibition. Despite a clear biological effect on downstream B cell activation has been observed in patients treated with CTLA-4-Ig (abatacept) and with monoclonal antibodies targeting CD40 and ICOSL, the clinical efficacy of this approach has so far yielded mixed results; while the anti-CD40 monoclonal antibody iscalimab showed significant improvement in systemic disease activity compared to placebo, two large RCTs with abatacept and a phase IIa RCT with an anti-ICOSL monoclonal antibody (prezalumab) failed to reach their primary endpoints. Although the discrepancies between biological and clinical efficacy of targeting T cell co-stimulation on pSS remain unresolved, several factors including drug bioavailability and receptor occupancy, patient stratification based on T-cell related biomarkers and the choice of study outcome are likely to play an important role and form the basis for further work towards the quest for a disease-modifying biologic therapy in pSS.

Original languageEnglish
Pages (from-to)222-227
Number of pages6
JournalClinical and Experimental Rheumatology
Volume38
Issue number4
Publication statusPublished - 1-Jul-2020

Keywords

  • Sjogren's syndrome
  • T cell co-stimulation and co-inhibition
  • CTLA-4-Ig
  • anti-CD40
  • anti-ICOSL
  • ABATACEPT TREATMENT
  • B-CELL
  • EPITHELIAL-CELLS
  • DISEASE-ACTIVITY
  • HYPER-IGM
  • EXPRESSION
  • CTLA-4
  • CD40
  • SERUM
  • DIFFERENTIATION

Cite this